Skip to main content

Defence equipment of Rs 1.5 lakh cr to be procured from domestic companies

To keep you updated, we send Defence News to your mailbox. In case, you wish to Unsubscribe Click Here
The Economic Times

Defence News

Dear Reader,

Just catching up? Here are the top defence stories from the day...
Defence equipment of Rs 1.5 lakh cr to be procured from domestic companiesDefence equipment of Rs 1.5 lakh cr to be procured from domestic companies
​​The Defence Ministry was scheduled to take up two of India's biggest-ever fighter aircraft projects worth Rs 1.3 lakh crore for discussion in a crucial meeting this week including buying 97 new LCA Mark 1A fighter aircraft and indigenously upgrading 84 Su-30 MKI combat planes. Read more
Navy scales up deployments, from counter piracy missions to submarine operationsNavy scales up deployments, from counter piracy missions to submarine operations
The pace of continuous deployment of ships and submarines is reflected in the number of days Indian Navy assets were at sea in the past year. Sources said that deployments accounted for over 9400 ship days, close to 1150 submarine days and almost 15000 hours of flying in the past year. Read more
Sixteen more hostages freed from Gaza as part of Israeli-Hamas truceSixteen more hostages freed from Gaza as part of Israeli-Hamas truce
The hostages freed were among some 240 people seized by Hamas gunmen during a rampage into southern Israel on Oct. 7 in which Israel says 1,200 people were killed. Israel's bombardment of Gaza in retaliation has killed more than 15,000 Gazans, according to health authorities in the Palestinian enclave. Read more
30 more Myanmar soldiers airlifted to Moreh from Mizoram30 more Myanmar soldiers airlifted to Moreh from Mizoram
Indian Air Force helicopters have airlifted 104 Myanmar army personnel from Mizoram to Moreh in Manipur, including 30 more who surrendered before the Assam Rifles/Mizoram Police. The situation in Mizoram remains tense due to recent clashes between rebel groups and military junta in Myanmar's Chin State. The situation is further tense in Mizoram due to the recent airstrike by the Myanmar army. Read more
icon
China rejects Philippine claim of fighter jet fly-byChina rejects Philippine claim of fighter jet fly-by
China's defense ministry dismisses Philippines' claim of Chinese fighter jets disrupting joint patrols with Australia as "groundless" and "not true," according to a ministry spokesperson. Read more
South Koreans want their own nukesSouth Koreans want their own nukes
The alliance with the United States has allowed South Korea to build a powerful democracy, its citizens confident that Washington would protect them if Pyongyang ever acted on its dream of unifying the Korean Peninsula under its own rule. Read more
EU defence spending at record 240 bn euros in 2022EU defence spending at record 240 bn euros in 2022
The European Defence Agency (EDA) said six countries had increased their spending by over 10 percent, with NATO applicant Sweden splashing over 30 percent more. Read more
Syrians lead push to create global chemical weapons tribunalSyrians lead push to create global chemical weapons tribunal
A dozen Syrian rights groups, international legal experts and others have quietly spent two years laying the groundwork for a new treaty-based court which could put on trial alleged users of banned toxic agents worldwide. Read more
Thanks for reading. Follow us on Twitter and Facebook.

Did you like today's newsletter?
hate it love it

* If someone forwarded this to you, subscribe here.

* If you do not want to receive this mailer, please unsubscribe here. To make sure this email is not sent to your "junk/spam" folder, select the email and add the sender to your Address Book.

© 2023 Times Internet Limited

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More